Business Wire

Lumen Bioscience Raises $16M Series B Financing to Accelerate Clinical Development of Accessible Biologic Drugs

SEATTLE--(BUSINESS WIRE)--Lumen Bioscience, a clinical-stage biopharmaceutical company developing biologic drugs for highly prevalent diseases, today announced the closing of a $16 million Series B ...
Seeking Alpha

Lumen Bioscience's LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial

SEATTLE, April 3, 2025 /PRNewswire/ -- In a landmark achievement for its pioneering spirulina-based drug development platform, Lumen announced today top-line results from the sentinel cohort of its ...
NBC4 Columbus

Lumen Bioscience Expands Board and Leadership Team to Advance Clinical Pipeline of Novel Oral Biologics

SEATTLE, Oct. 8, 2025 /PRNewswire/ -- Lumen Bioscience—a clinical-stage biotech developing orally delivered biologics—today announced key leadership enhancements. Jeff Raikes has joined the company's ...
Skagit Valley Herald

Lumen Bioscience's LMN-201 Achieves 100% Initial C. difficile Clinical Cure in Preliminary Cohort of RePreve Trial | | goskagit.com

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.